Regeneron Pharmaceuticals... (REGN)
Regeneron Pharmaceuticals Statistics
Share Statistics
Regeneron Pharmaceuticals has 107.51M shares outstanding. The number of shares has increased by -0.79% in one year.
Shares Outstanding | 107.51M |
Shares Change (YoY) | -0.79% |
Shares Change (QoQ) | -0.52% |
Owned by Institutions (%) | 86.35% |
Shares Floating | 105.4M |
Failed to Deliver (FTD) Shares | 3 |
FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 2.12M, so 1.96% of the outstanding shares have been sold short.
Short Interest | 2.12M |
Short % of Shares Out | 1.96% |
Short % of Float | 2% |
Short Ratio (days to cover) | 2.48 |
Valuation Ratios
The PE ratio is 17.42 and the forward PE ratio is 15.46. Regeneron Pharmaceuticals's PEG ratio is 1.68.
PE Ratio | 17.42 |
Forward PE | 15.46 |
PS Ratio | 5.41 |
Forward PS | 3.4 |
PB Ratio | 2.62 |
P/FCF Ratio | 20.97 |
PEG Ratio | 1.68 |
Enterprise Valuation
Regeneron Pharmaceuticals has an Enterprise Value (EV) of 77.08B.
EV / Sales | 5.43 |
EV / EBITDA | 14.49 |
EV / EBIT | 17.44 |
EV / FCF | 21.03 |
Financial Position
The company has a current ratio of 4.73, with a Debt / Equity ratio of 0.09.
Current Ratio | 4.73 |
Quick Ratio | 3.95 |
Debt / Equity | 0.09 |
Debt / EBITDA | 0.51 |
Debt / FCF | 0.74 |
Interest Coverage | 72.3 |
Financial Efficiency
Return on Equity is 15.03% and Return on Invested Capital is 10.89%.
Return on Equity | 15.03% |
Return on Assets | 11.69% |
Return on Invested Capital | 10.89% |
Revenue Per Employee | $940.16K |
Profits Per Employee | $292.11K |
Employee Count | 15,106 |
Asset Turnover | 0.38 |
Inventory Turnover | 0.64 |
Taxes
Income Tax | 367.3M |
Effective Tax Rate | 7.68% |
Stock Price Statistics
The stock price has increased by -34.87% in the last 52 weeks. The beta is 0.43, so Regeneron Pharmaceuticals's price volatility has been higher than the market average.
Beta | 0.43 |
52-Week Price Change | -34.87% |
50-Day Moving Average | 679.17 |
200-Day Moving Average | 887.72 |
Relative Strength Index (RSI) | 32.87 |
Average Volume (20 Days) | 1.01M |
Income Statement
In the last 12 months, Regeneron Pharmaceuticals had revenue of 14.2B and earned 4.41B in profits. Earnings per share was 40.9.
Revenue | 14.2B |
Gross Profit | 12.23B |
Operating Income | 3.99B |
Net Income | 4.41B |
EBITDA | 5.32B |
EBIT | 4.84B |
Earnings Per Share (EPS) | 40.9 |
Balance Sheet
The company has 2.49B in cash and 2.7B in debt, giving a net cash position of -216.2M.
Cash & Cash Equivalents | 2.49B |
Total Debt | 2.7B |
Net Cash | -216.2M |
Retained Earnings | 31.67B |
Total Assets | 37.76B |
Working Capital | 26.4B |
Cash Flow
In the last 12 months, operating cash flow was 4.42B and capital expenditures -755.9M, giving a free cash flow of 3.66B.
Operating Cash Flow | 4.42B |
Capital Expenditures | -755.9M |
Free Cash Flow | 3.66B |
FCF Per Share | 33.96 |
Margins
Gross margin is 86.13%, with operating and profit margins of 28.1% and 31.07%.
Gross Margin | 86.13% |
Operating Margin | 28.1% |
Pretax Margin | 33.66% |
Profit Margin | 31.07% |
EBITDA Margin | 37.45% |
EBIT Margin | 28.1% |
FCF Margin | 25.8% |
Dividends & Yields
REGN does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | 5.74% |
FCF Yield | 4.77% |
Analyst Forecast
The average price target for REGN is $1015, which is 66.3% higher than the current price. The consensus rating is "Buy".
Price Target | $1015 |
Price Target Difference | 66.3% |
Analyst Consensus | Buy |
Analyst Count | 22 |
Scores
Altman Z-Score | 16.22 |
Piotroski F-Score | 6 |